AUSTIN, Texas, Sept. 19, 2017 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced that management will present at Cantor Fitzgerald’s Global Healthcare Conference to be held September 25 -27, 2017, in New York, NY. The investor presentation will begin at 10:20 a.m. Eastern time on Tuesday, September 26, 2017. The presentation will be webcast live and may... Read more
AUSTIN, Texas, Aug. 29, 2017 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX), and Sutter Health, a not-for-profit health system in Northern California, today announced a collaboration to help advance patient care by improving the health network’s ability to quickly and accurately diagnose a range of conditions, including Cystic Fibrosis, gastrointestinal illness, and respiratory tract infections. Using a... Read more
AUSTIN, Texas, Aug. 29, 2017 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX), and Sutter Health, a not-for-profit health system in Northern California, today announced a collaboration to help advance patient care by improving the health network’s ability to quickly and accurately diagnose a range of conditions, including Cystic Fibrosis, gastrointestinal illness, and respiratory tract infections. Using a... Read more
AUSTIN, Texas, July 24, 2017 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced that it has received FDA clearance for the ARIES®C. difficile Assay, a moderate complexity, sample to answer test for rapid detection of C. difficile. The ARIES®C. difficile Assay detects both toxin A and toxin B, which may reduce the probability of a false... Read more
AUSTIN, Texas, July 24, 2017 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced that it has received FDA clearance for the ARIES®C. difficile Assay, a moderate complexity, sample to answer test for rapid detection of C. difficile. The ARIES®C. difficile Assay detects both toxin A and toxin B, which may reduce the probability of a false... Read more
AUSTIN, Texas, June 28, 2017 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced that it has received CE-IVD marking for the ARIES® Norovirus Assay, an easy to use, sample to answer test for rapid detection and differentiation of norovirus genogroup I and II from stool specimens of individuals with symptoms of acute gastroenteritis. The CDC reports... Read more
AUSTIN, Texas, June 28, 2017 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced that it has received CE-IVD marking for the ARIES® Norovirus Assay, an easy to use, sample to answer test for rapid detection and differentiation of norovirus genogroup I and II from stool specimens of individuals with symptoms of acute gastroenteritis. The CDC reports... Read more
AUSTIN, Texas, June 5, 2017 /PRNewswire/ –Luminex Corporation (NASDAQ: LMNX) today announced that Japan’s Central Social Insurance Medical Council has approved the recommendation by the Japanese Ministry of Health, Labor and Welfare (MHLW) to provide reimbursement for two VERIGENE® assays: the Gram-Positive Blood Culture (BC-GP) test and the Gram-Negative Blood Culture (BC-GN) test. The MHLW established reimbursement went into... Read more
AUSTIN, Texas, May 25, 2017 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) announced today that management will present at the Jefferies 2017 Global Healthcare Conference on Thursday, June 8 at 8:30am ET in New York. The investor presentation will be webcast live and may be accessed at Luminex Corporation’s website at http://www.luminexcorp.com. Simply log on to the web at... Read more
AUSTIN, Texas, May 25, 2017 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) announced today that management will present at the Jefferies 2017 Global Healthcare Conference on Thursday, June 8 at 8:30am ET in New York. The investor presentation will be webcast live and may be accessed at Luminex Corporation’s website at http://www.luminexcorp.com. Simply log on to the web at... Read more